论文部分内容阅读
目的探讨血脂康治疗不稳定型心绞痛(UA)患者的疗效与安全性及对近中期心血管事件的影响。方法共入选84例不稳定型心绞痛患者,随机分为血脂康组(43例)和辛伐他汀组(41例):①血脂康组:43例UA患者,其中男性31例,女性12例。平均62.5岁。②辛伐他汀组:41例UA患者,其中男性30例,女性11例,平均年龄62.2岁。分别于3、6、12个月时复查血脂,并对临床事件作随访登记,同时观察用药安全性。结果血脂康组与辛伐他汀组均能有效降低UA患者血清总胆固醇(TC)及低密度脂蛋白胆固醇(LDL-C)水平,随访期间两组均能使心肌梗死发生率、再住院率及再次血管重建率明显降低。两组之间比较差异无统计学意义。结论血脂康能有效降低UA患者血清TC及LDL-C水平,预防心血管事件的发生。具有良好的安全性和耐受性。
Objective To investigate the efficacy and safety of Xuezhikang in the treatment of patients with unstable angina pectoris (UA) and its influence on the recent and mid-term cardiovascular events. Methods A total of 84 patients with unstable angina were enrolled and randomly divided into Xuezhikang group (43 cases) and simvastatin group (41 cases). Xuezhikang group: 43 UA patients, including 31 males and 12 females. Average 62.5 years old. Simvastatin group: 41 UA patients, including 30 males and 11 females, with an average age of 62.2 years. Blood lipids were reviewed at 3, 6, and 12 months respectively, and clinical events were followed up for registration. At the same time, medication safety was observed. Results Serum total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) levels were significantly decreased in both Xuezhikang and simvastatin groups. During the follow-up period, both the incidence of myocardial infarction, rehospitalization rate, The rate of revascularization was significantly lower again. No significant difference between the two groups was statistically significant. Conclusion Xuezhikang can effectively reduce the levels of serum TC and LDL-C in patients with UA and prevent the occurrence of cardiovascular events. Has good safety and resistance.